MedDataX Logo

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

NCT00794417 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-12-10

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).

Conditions

  • Advanced Carcinoma
  • Non-small Cell Lung Cancer

Interventions

DRUG

Aflibercept

Administered in combination with the other two interventions via intravenous infusion.

DRUG

Pemetrexed

Administered in combination with the other two interventions via intravenous infusion.

DRUG

Cisplatin

Administered in combination with the other two interventions via intravenous infusion.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Regeneron Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Canada

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00794417 on ClinicalTrials.gov